Moxalactam versus clindamycin plus tobramycin for the treatment of puerperal infections.

Abstract

Sixty women with the diagnosis of puerperal endometritis were randomized to receive either moxalactam (n = 29) or the combination of clindamycin and tobramycin (n = 31) as therapy for their infection. Endometrial bacteriology consisted of mixed flora, both aerobic and anaerobic gram-positive and gram-negative organisms. Clinical cure was achieved in 27 (93%) of the moxalactam-treated patients and 28 (90%) of those given combination therapy. The two failures of moxalactam therapy were associated with enterococcal infection. Failures of clindamycin/tobramycin therapy were due to enterococcal infection, abscess formation, and moderately severe diarrhea. This study indicates that moxalactam is as effective and safe as the combination of clindamycin/tobramycin for the treatment of postpartum endometritis.

• Authors: J G Pastorek 2nd, S Faro, K E Aldridge, S K Nicaud
• Journal: Southern medical journal (South Med J) Vol. 80 Issue 9 Pg. 1116-9 (Sep 1987) ISSN: 0038-4348 [Print] United States
• PMID: 3306943 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Clindamycin
• Moxalactam
• Tobramycin

Topics

• Clindamycin (therapeutic use)
• Clinical Trials as Topic
• Drug Therapy, Combination
• Endometritis (drug therapy)
• Female
• Humans
• Moxalactam (therapeutic use)
• Pregnancy
• Prospective Studies
• Puerperal Infection (drug therapy)
• Random Allocation
• Tobramycin (therapeutic use)